Q3 2024 Holdings
Filed 2024-11-14 | 93 holdings | $9.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| BeiGene, Ltd.(ONC) | SPONSORED ADR | 07725L102 | $2.4B | 10,568,897 | 24.6% |
| Incyte Corporation(INCY) | COM | 45337C102 | $2.0B | 30,739,020 | 21.1% |
| Acadia Pharmaceuticals Inc.(ACAD) | COM | 004225108 | $659.5M | 42,877,916 | 6.8% |
| Summit Therapeutics Inc.(SMMT) | COM | 86627T108 | $534.9M | 24,424,865 | 5.5% |
| Madrigal Pharmaceuticals, Inc.(MDGL) | COM | 558868105 | $419.0M | 1,974,590 | 4.3% |
| Revolution Medicines, Inc.(RVMD) | COM | 76155X100 | $343.3M | 7,569,090 | 3.6% |
| Rhythm Pharmaceuticals, Inc.(RYTM) | COM | 76243J105 | $335.2M | 6,398,366 | 3.5% |
| Insmed Incorporated(INSM) | COM PAR $.01 | 457669307 | $322.4M | 4,415,918 | 3.3% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $283.8M | 5,995,929 | 2.9% |
| Bicycle Therapeutics plc(BCYC) | SPONSORED ADS | 088786108 | $212.7M | 9,399,960 | 2.2% |
| Edgewise Therapeutics, Inc.(EWTX) | COM | 28036F105 | $155.9M | 5,840,059 | 1.6% |
| Replimune Group, Inc.(REPL) | COM | 76029N106 | $121.1M | 11,045,336 | 1.3% |
| Alkermes plc(ALKS) | SHS | G01767105 | $117.0M | 4,181,751 | 1.2% |
| Denali Therapeutics Inc.(DNLI) | COM | 24823R105 | $108.7M | 3,731,695 | 1.1% |
| Insmed Incorporated | Note 0.75% 6/1/2028 | 457669AB5 | $98.3M | $42,850,000 | 1.0% |
| Ultragenyx Pharmaceutical Inc.(RARE) | COM | 90400D108 | $87.6M | 1,576,114 | 0.9% |
| Nurix Therapeutics, Inc.(NRIX) | COM | 67080M103 | $87.2M | 3,882,125 | 0.9% |
| Entrada Therapeutics, Inc.(TRDA) | COM | 29384C108 | $77.8M | 4,865,819 | 0.8% |
| Immatics N.V.(IMTX) | SHS | N44445109 | $73.5M | 6,443,398 | 0.8% |
| AbCellera Biologics Inc.(ABCL) | COM | 00288U106 | $71.6M | 27,525,640 | 0.7% |
| Kiniksa Pharmaceuticals International, plc(KNSA) | ORD SHS CL A | G52694109 | $70.4M | 2,818,323 | 0.7% |
| IGM Biosciences, Inc.(1K0) | COM | 449585108 | $67.7M | 4,092,310 | 0.7% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $60.7M | 111,904 | 0.6% |
| Stoke Therapeutics, Inc.(STOK) | COM | 86150R107 | $53.7M | 4,368,443 | 0.6% |
| Immunocore Holdings plc(IMCR) | ADS | 45258D105 | $47.2M | 1,515,318 | 0.5% |
| Kodiak Sciences Inc.(KOD) | COM | 50015M109 | $45.2M | 17,310,490 | 0.5% |
| Sera Prognostics, Inc.(SERA) | CLASS A COM | 81749D107 | $42.4M | 5,434,399 | 0.4% |
| Crispr Therapeutics AG(CRSP) | NAMEN AKT | H17182108 | $39.6M | 843,075 | 0.4% |
| Xenon Pharmaceuticals Inc.(XENE) | COM | 98420N105 | $39.1M | 993,679 | 0.4% |
| Immunovant, Inc.(IMVT) | COM | 45258J102 | $34.9M | 1,225,410 | 0.4% |
| Cerus Corporation(CERS) | COM | 157085101 | $33.9M | 19,477,339 | 0.4% |
| Ideaya Biosciences, Inc.(IDYA) | COM | 45166A102 | $33.6M | 1,062,123 | 0.3% |
| Roivant Sciences Ltd.(ROIV) | SHS | G76279101 | $32.3M | 2,798,716 | 0.3% |
| Akero Therapeutics, Inc.(AKRO) | COM | 00973Y108 | $31.5M | 1,097,082 | 0.3% |
| Krystal Biotech, Inc.(KRYS) | COM | 501147102 | $30.9M | 169,934 | 0.3% |
| Celcuity Inc.(CELC) | COM | 15102K100 | $28.0M | 1,874,978 | 0.3% |
| Monte Rosa Therapeutics, Inc.(GLUE) | COM | 61225M102 | $26.1M | 4,916,095 | 0.3% |
| Dyne Therapeutics, Inc.(DYN) | COM | 26818M108 | $24.1M | 672,096 | 0.3% |
| Biomea Fusion, Inc.(BMEA) | COM | 09077A106 | $21.3M | 2,108,949 | 0.2% |
| Bicara Therapeutics Inc.(BCAX) | COM | 055477103 | $21.2M | 833,333 | 0.2% |
| Prelude Therapeutics Inc.(PRLD) | COM | 74065P101 | $21.0M | 10,123,824 | 0.2% |
| Centessa Pharmaceuticals plc(CNTA) | SPONSORED ADS | 152309100 | $19.6M | 1,227,178 | 0.2% |
| Neurogene Inc.(NGNE) | COM | 64135M105 | $19.1M | 456,015 | 0.2% |
| Praxis Precision Medicines, Inc.(PRAX) | COM | 74006W207 | $18.6M | 323,105 | 0.2% |
| Alumis Inc.(ALMS) | COM | 022307102 | $16.7M | 1,562,500 | 0.2% |
| Merus N.V. | COM | N5749R100 | $15.0M | 300,000 | 0.2% |
| TScan Therapeutics, Inc.(TCRX) | COM | 89854M101 | $13.9M | 2,784,792 | 0.1% |
| Neumora Therapeutics, Inc.(NMRA) | COM | 640979100 | $13.7M | 1,034,600 | 0.1% |
| Xencor, Inc.(XNCR) | COM | 98401F105 | $13.5M | 670,431 | 0.1% |
| 2seventy bio, Inc.(TSVT*) | COMMON STOCK | 901384107 | $11.8M | 2,497,526 | 0.1% |